Issue Date: January 9, 2012
Forma, Boehringer Sign Oncology Pact
Forma Therapeutics and Boehringer Ingelheim have formed an R&D collaboration aimed at discovering small molecules that act against oncology-relevant protein-protein interactions. Forma will receive $65 million in up-front payments and research funding to screen for and optimize compounds over the next four years. It could get up to $750 million in milestone payments as well. Forma is based on science developed at the Broad Institute. It also has partnerships with Genentech, Eisai, and Novartis.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society